Transcript
Speaker: Edison Group recently published a review note on IP Group, which allows investors to tap into the vast opportunity set of innovative private companies and IP rights. We believe these investments align with some of the most compelling investment themes over the next decade, um spanning anti-obesity drugs, gene sequencing, AI infrastructure, quantum computing, fusion energy, green hydrogen and autonomous vehicles, among others.
Speaker: IP Group remains focused on doubling down on a narrow set of more mature growth stage businesses to generate returns. on The company's NAV per share increased by 13% in FY25, primarily on the back of a £126.4 million pounds increase in the value of its royalty and milestone exposure to Pfizer's Medsera-derived obesity pipeline.
Speaker: We believe that at the current discount to NAV, IP Group's shares offer a compelling asymmetric return profile from its exposure to potential future income streams from these anti-obesity products.
